Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related TEVA
Will Allergan Buy Gilead? Don't Count On 'The Mother Of All Blockbusters'
Allergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma
Teva: Buy For Today's Value And Tomorrow's Growth (Seeking Alpha)
Related QEP
10 Biggest Price Target Changes For Wednesday
3 Natural Gas And Oil Companies That Insiders Are Buying

Analysts at JP Morgan downgraded Teva Pharmaceutical Industries (NYSE: TEVA) from “overweight” to “neutral.” The target price for Teva has been lowered from $45 to $43. Teva's shares closed at $38.88 yesterday.

Deutsche Bank downgraded QEP Resources (NYSE: QEP) from “buy” to “hold.” The target price for QEP Resources has been lowered from $37 to $34. QEP Resources' shares closed at $28.78 yesterday.

Baird downgraded Brady (NYSE: BRC) from “outperform” to “neutral.” The target price for Brady has been lowered from $41 to $33. Brady's shares closed at $30.52 yesterday.

Analysts at DA Davidson downgraded Under Armour (NYSE: UA) from “buy” to “neutral.” Under Armour's shares closed at $80.59 yesterday.

Latest Ratings for TEVA

DateFirmActionFromTo
Sep 2016OppenheimerUpgradesPerformOutperform
Aug 2016Leerink SwannMaintainsOutperform
Aug 2016BTIG ResearchMaintainsBuy

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (BRC + QEP)

View Comments and Join the Discussion!